AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- Reduced L-selectin (CD62L[superscript]Low) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
"Reduced expression of CD62L can identify tumor-specific T cells in lymph nodes draining murine tumors. Here, we examined whether this strategy could isolate tumor-specific T cells from vaccinated patients. Tumor vaccine-draining lymph node (TVDLN) T cells of seven patients were separated into populations with reduced (CD62L[superscript]Low) or high levels of CD62L (CD62L[superscript]High)," scientists writing in the journal Cellular Immunology report.
"Effector T cells generated from CD62L[superscript]Low cells maintained or enriched the autologous tumor-specific type 1 cytokine response compared to unseparated TVDLN T cells in four of four patients showing tumor-specific cytokine secretion," stated Sybren L. Meijer and collaborators at the Providence Portland Medical Center. "Interestingly, effector T cells generated froth CD62L[superscript]Low or CD62L[superscript]High TVDLN were polarized towards a dominant type 1 or type 2 cytokine profile, respectively. For CD62L[superscript]Low T cells the type 1 cytokine profile appeared determined prior to ...
Source: HighBeam Research, Reduced L-selectin expression identifies tumor-specific type 1 T...